The Editor’s Roundtable: Statin Therapy in Acute Coronary Syndrome

Published:November 18, 2006DOI:https://doi.org/10.1016/j.amjcard.2006.10.003
      This activity is supported by an educational grant from Pfizer, Inc., New York, New York.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Scandinavian Simvastatin Survival Study Group
        Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • Rouleau J.L.
        • Rutherford J.D.
        • Cole T.G.
        • Brown L.
        • Warnica W.
        • Arnold J.M.O.
        • Wun C.
        • Davis B.R.
        • Braunwald E.
        • Cholesterol and Recurrent Events Trial Investigators
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        N Engl J Med. 1998; 339: 1349-1357
        • Arntz H.R.
        • Agrawal R.
        • Wunderlich W.
        • Schnitzer L.
        • Stern R.
        • Fischer F.
        • Schultheiss H.P.
        Beneficial effects of pravastatin (+/−cholestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
        Am J Cardiol. 2000; 86: 1293-1298
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • Rader D.J.
        • Rouleau J.L.
        • Belder R.
        • Joyal S.V.
        • Hill K.A.
        • Pfeffer M.A.
        • Skene A.M.
        Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • de Lemos J.A.
        • Blazing M.A.
        • Wiviott S.D.
        • Lewis E.F.
        • Fox K.A.
        • White H.D.
        • Rouleau J.L.
        • Pedersen T.R.
        • Gardner L.H.
        • Mukherjee R.
        • Ramsey K.E.
        • Palmisano J.
        • Bilheimer D.W.
        • Pfeffer M.A.
        • Califf R.M.
        • Braunwald E.
        Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
        JAMA. 2004; 292: 1307-1316
        • Dupuis J.
        • Tardif J.C.
        • Cernacek P.
        • Theroux P.
        Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes.
        Circulation. 1999; 99: 3227-3233
        • Kayikcioglu M.
        • Can L.
        • Evrengul H.
        • Payzin S.
        • Kultursay H.
        The effect of statin therapy on ventricular late potentials in acute myocardial infarction.
        Int J Cardiol. 2003; 90: 63-72
        • Kinlay S.
        • Schwartz G.G.
        • Olsson A.G.
        • Rifai N.
        • Leslie S.J.
        • Sasiela W.J.
        • Szarek M.
        • Libby P.
        • Ganz P.
        High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
        Circulation. 2003; 108: 1560-1566
        • Pedersen T.R.
        • Jahnsen K.E.
        • Vatn S.
        • Semb A.G.
        • Kontny F.
        • Zalmai A.
        • Nerdrum T.
        Benefits of early lipid-lowering intervention in high-risk patients: the lipid intervention strategies for coronary patients study.
        Clin Ther. 2000; 22: 949-960
        • Schwartz G.G.
        • Olsson A.G.
        • Ezekowitz M.D.
        • Ganz P.
        • Oliver M.F.
        • Waters D.
        • Zeiher A.
        • Chaitman B.R.
        • Leslie S.
        • Stern T.
        Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
        JAMA. 2001; 285: 1711-1718
        • Waters D.D.
        • Schwartz G.G.
        • Olsson A.G.
        • Zeiher A.
        • Oliver M.F.
        • Ganz P.
        • Ezekowitz M.
        • Chaitman B.R.
        • Leslie S.J.
        • Stern T.
        Effects of atorvastatin on stroke in patients with unstable angina or non–Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
        Circulation. 2002; 106: 1690-1695